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AbstrACt
Introduction Patients presenting with acute 
undifferentiated breathlessness are commonly 
encountered in admissions units across the UK. Existing 
blood biomarkers have clinical utility in distinguishing 
patients with single organ pathologies but have poor 
discriminatory power in multifactorial presentations. 
Evaluation of volatile organic compounds (VOCs) in 
exhaled breath offers the potential to develop biomarkers 
of disease states that underpin acute cardiorespiratory 
breathlessness, owing to their proximity to the 
cardiorespiratory system. To date, there has been no 
systematic evaluation of VOC in acute cardiorespiratory 
breathlessness. The proposed study will seek to use 
both offline and online VOC technologies to evaluate the 
predictive value of VOC in identifying common conditions 
that present with acute cardiorespiratory breathlessness.
Methods and analysis A prospective real-world 
observational study carried out across three acute 
admissions units within Leicestershire. Participants with 
self-reported acute breathlessness, with a confirmed 
primary diagnosis of either acute heart failure, community-
acquired pneumonia and acute exacerbation of asthma or 
chronic obstructive pulmonary disease will be recruited 
within 24 hours of admission. Additionally, school-age 
children admitted with severe asthma will be evaluated. 
All participants will undergo breath sampling on 
admission and on recovery following discharge. A range 
of online technologies including: proton transfer reaction 
mass spectrometry, gas chromatography ion mobility 
spectrometry, atmospheric pressure chemical ionisation-
mass spectrometry and offline technologies including gas 
chromatography mass spectroscopy and comprehensive 
two-dimensional gas chromatography-mass spectrometry 
will be used for VOC discovery and replication. For offline 
technologies, a standardised CE-marked breath sampling 
device (ReCIVA) will be used. All recruited participants 
will be characterised using existing blood biomarkers 
including C reactive protein, brain-derived natriuretic 
peptide, troponin-I and blood eosinophil levels and further 
evaluated using a range of standardised questionnaires, 
lung function testing, sputum cell counts and other 
diagnostic tests pertinent to acute disease.
Ethics and dissemination The National Research Ethics 
Service Committee East Midlands has approved the 
study protocol (REC number: 16/LO/1747). Integrated 
Research Approval System (IRAS) 198921. Findings will 
be presented at academic conferences and published 
in peer-reviewed scientific journals. Dissemination will 
be facilitated via a partnership with the East Midlands 
strengths and limitations of this study
 ► A pragmatic real-world, prospective, observational 
study across three admission units that focuses on 
the systematic discovery and replication of volatile 
organic compound (VOC) in acutely breathless pa-
tients using both online and offline technologies.
 ► The proposed study is the largest of its kind in acute 
disease to characterise VOC with a range of addi-
tional assessments that will build a comprehensive 
phenotype of acute cardiorespiratory exacerbations.
 ► The proposed study will build an infrastructure for 
research and subsequent evaluation of VOC in in-
terventional trials within acute cardiorespiratory 
exacerbations.
 ► Prior acute treatment exposure will need to be ac-
counted for when evaluating potential discriminative 
biomarkers.
 ► VOC technologies are not currently suited for de-
ployment in patients that are of high clinical acuity.
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Academic Health Sciences Network and via interaction with all UK-
funded Medical Research Council and Engineering and Physical Sciences 
Research Council molecular pathology nodes.
trial registration number NCT03672994.
IntroduCtIon 
Breathlessness is a common symptom of cardiorespiratory 
illnesses that has a significant direct impact on patients’ 
well-being as well as a substantial economic burden on 
healthcare systems.1 Although its aetiologies can be vari-
able, exacerbations of common complex chronic cardio-
respiratory conditions account for approximately 70% 
of acute presentations with breathlessness, namely exac-
erbations of asthma and chronic obstructive pulmonary 
disease (COPD), acute heart failure and community 
acquired pneumonia.2 Moreover, moderate and severe 
breathlessness is significantly associated with all-cause, 
cardiovascular and COPD mortality.3 As a consequence, 
symptomatic breathlessness warrants rapid evaluation 
and targeted diagnostics at presentation.
Diagnostic evaluation of acute breathlessness is heavily 
reliant on blood-based biomarkers for example, C reactive 
protein (CRP), brain-derived natriuretic peptide (BNP), 
troponin and on occasions blood eosinophil levels. These 
biomarkers have clinical utility primarily in patients with 
single pathologies but have poor discriminatory power 
in patients with multifactorial presentations of acute 
breathlessness.4 There is therefore an unmet need for 
the development of sensitive and specific biomarkers that 
differentiate acute breathlessness from its recovery and 
the common cardiorespiratory conditions that present 
with acute breathlessness.
CRP plays an important role in diagnosing breath-
lessness caused by an underlying bacterial pneumonia,5 
as well as predicting mortality in patients with chronic 
obstructive pulmonary disease (COPD).6 BNP is routinely 
used in acute settings to support the diagnosis of acute 
heart failure.7The European Society of Cardiology recom-
mends BNP threshold values of <100 pg/mL to rule out 
acute congestive cardiac failure and values >500 pg/mL as 
diagnostic of acute exacerbations of heart failure.8
The role of peripheral blood eosinophil count in airway 
inflammation was poorly understood up until the second 
half of the 19th century when Paul Ehrlich, a German 
physician and Nobel prize winner, introduced eosin in his 
technique for white cell differentiation in 1879.9 Consid-
erable advances in the field of airway inflammation and 
the role of eosinophils have taken place since.10–12 More 
recently, Bafadhel et al13 suggested that peripheral blood 
eosinophil count can be used to direct corticosteroid 
therapy during COPD exacerbations in single-centre 
study.
Currently, blood biomarkers together with clinical, 
physiological and imaging parameters are used in 
diagnosing the cause of acute breathlessness. Blood 
biomarkers may be less specific as they originate far from 
the target organs of interest (the heart and the lungs in 
cardiorespiratory disease). Sputum, although potentially 
a more definitive lung-specific matrix, is comparatively 
difficult to obtain particularly in acutely unwell patients, 
limiting its use in acute disease and highlighting the need 
for better biomarkers. Ideally, these biomarkers would 
have the following characteristics: (1) they would orig-
inate from the target organ of interest, (2) they would 
significantly add value to conventional risk scoring and 
diagnostic algorithms in acute breathlessness, (3) they 
would be minimally invasive and suitable for rapid point 
of care diagnosis in emergency rooms and acute admis-
sions units and (4) they would have diagnostic value in 
patients with multifactorial acute breathlessness.
Exhaled breath contains thousands of volatile organic 
compounds (VOCs) that reflect biological processes 
occurring in the host both locally in the airways and 
systematically offering the potential to develop more effec-
tive biomarkers in acutely breathless patients (figure 1).
The proposed programme of research will use a combi-
nation of offline and online technologies to identify and 
evaluate the diagnostic and prognostic value of VOC in 
patients with acute cardiorespiratory-related breathless-
ness (figure 2).
Exhaled breath analysis of volatile chemicals offers the 
potential to develop more effective biomarkers in acutely 
breathless patients. The use of breath analysis for disease 
diagnostics dates back to ancient Greeks where physicians 
used exhaled breath to diagnose different diseases. Breath 
odours allow correct associations to certain diseases. For 
example, the sweet smell of diabetic ketoacidosis, the 
fishy smell of breath associated to liver illness, the urine-
like odour of kidney disease and the smell of the breath 
Figure 1 Relationship between lung proximity and degree 
of invasiveness of different lung matrices. The figure plots the 
level of invasiveness of various lung matrices in relation to 
their proximity to the lung. Given their pathological relevance, 
the degree of invasiveness of bronchoalveolar lavage (BAL) 
and lung biopsy makes them less favourable in diagnosing 
respiratory diseases.
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of patients with lung abscesses caused by the proliferation 
of anaerobic bacteria.14–17
More recently, exhaled breath analysis has demon-
strated early proof of concept in the diagnosis of acute 
heart failure, and ventilator associated pneumonia.18 The 
validity of breath analysis has also been demonstrated in 
breathless children.19 This population is likely to prefer 
breath-based tests, as these are minimally invasive. Impor-
tantly, a variety of point-of-care sensors are now available 
to evaluate potential exhaled breath biomarkers in emer-
gency care settings.
A study by Van Berkel et al20 demonstrated the ability to 
distinguish COPD subjects from controls solely based on 
the presence of VOCs in breath, suggesting that analysis 
of VOC might be highly relevant for diagnosis of COPD. 
This established the basis of further studies of VOC in 
COPD21–25 recommending larger studies for validation.
Several other studies found that VOC profiling in diag-
nosing asthma is potentially feasible.26–32 This, however, 
has been done in relatively small numbers in stable 
disease.
Despite the novelty of non-invasive sampling technology 
and the growing interest in exhaled breath analysis, there 
remains a disappointing level of comparability across 
studies due to the lack of standardisation and appropriate 
data analysis methods. A recent systemic review by Anders 
Christiansen et al33 compared 11 publications reporting 
very heterogeneous designs, methods, patient group sizes, 
data analytics and, consequently, quite varying results.
To our knowledge, no other large studies exploring the 
use of breath biomarkers in profiling acute breathless-
ness have been completed. Several studies have explored 
the use of electronic nose (eNose) in stable disease with 
good discriminatory power in COPD,34 pneumonia35 and 
heart failure36 with relatively small sample size. While 
eNose has now been widely used in detecting various 
VOC patterns, gas chromatography mass spectroscopy 
(GC-MS), a largely validated methodology, remains the 
gold standard technique for detecting VOCs in exhaled 
breath. The focus of the current research study will be 
to evaluate acutely breathless cardiorespiratory patients 
using a combination of ‘discovery’ and near-patient care 
breath sampling technologies.
Medical Research Council (MRC) and Engineering and 
Physical Sciences Research Council have commissioned 
a series of molecular pathology nodes aimed at devel-
oping molecular signatures relevant to disease diagnosis 
and progression. This was triggered by the clear need 
for alliance between academic institutions, industry and 
National Health Service partners to enhance the benefits 
of stratified medicine for patients.37
University of Leicester and Loughborough University 
were awarded a joint molecular pathology node East 
Midlands Breathomics Pathology Node (EMBER), which 
this study forms a key part of.
MEthods And AnAlysIs
study design
A prospective real-world observational study across three 
acute admissions units within Leicestershire (two adult 
admissions units and one children’s assessment unit). The 
acute units routinely assess and treat cardiorespiratory 
admissions due to breathlessness in adults and children.
Participants with self-reported acute breathlessness, 
either requiring admission or a change in baseline treat-
ment, will be screened for the study. Informed consent 
will be obtained in all participants following a clinical 
review by a senior decision maker within 24 hours of acute 
admission (figure 3).
Figure 2 Multi-instrument use in breath sampling. Figure illustrates the various combinations of offline and online devices used 
in breath sampling and the relevant pros and cons. Offline and online technologies are used for the discovery and validation 
phases of the study, respectively. 
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objectives
Primary objective
 ► To evaluate the sensitivity, specificity, positive and 
negative predictive values of exhaled breath VOC 
biomarkers to differentiate acute breathlessness in 
cardiorespiratory patients.
Secondary objectives
 ► To replicate selected breath VOC biomarkers identi-
fied in acute breathlessness.
 ► To discover and replicate breath VOC biomarkers 
that differentiate the common cardiorespiratory 
conditions that cause acute breathlessness, specifi-
cally: (1) acute heart failure, (2) community-acquired 
pneumonia, (3) adult exacerbations of asthma and 
chronic obstructive pulmonary disease (COPD) and 
age-matched adults that do not have cardiorespiratory 
disease or breathlessness.
 ► To quantify the level of clinical uncertainty in the 
primary diagnosis using a 100 mm visual analogue 
scale (VAS) and independent clinical adjudication of 
case notes blinded to the following blood biomarkers: 
(1) CRP, (2) BNP, (3) troponin-I and (4) blood eosin-
ophils but not clinical history and acute presentation 
nor chest X-ray imaging. Potential discriminatory 
breath VOC biomarkers will be adjusted for clinical 
uncertainly in statistical models.
 ► To identify and replicate exhaled breath VOC 
biomarkers in school-age children treated in hospital 
for severe asthma attacks and compare these with 
age-matched healthy controls.
Exploratory endpoints (where applicable)
 ► To evaluate the dynamic profile of selected breath 
VOC between the acute state and the recovery state 
postexacerbation.
 ► To evaluate the relationship between exhaled VOC 
biomarkers and clinical outcomes including: (1) 
hospital readmission at 30 days and 60 days poste-
vent and (2) all-cause mortality over a 2-year period 
postadmission.
 ► To evaluate the relationship between breath VOC 
biomarkers and functional measures, for example, 
physical performance and activity.
 ► To explore potential breath VOC biomarkers of multi-
factorial acute breathlessness.
 ► To evaluate the relationship between diet, lifestyle 
and environment on breath VOC biomarkers.
sample size estimation
Preliminary data were used to conduct sample size 
estimates from a cohort of acutely breathless patients 
admitted to acute admissions units over a 6-month period 
(February 2017–August 2017). One hundred and twelve 
adult participants (asthma: 46, community-acquired 
pneumonia: 26 and COPD: 22) and 18 healthy controls 
were used for the analysis.
A panel of 10 prespecified aldehydes, based on liter-
ature search,31 38 39 were extracted from breath using 
GC-MS. The aldehydes were normalised to a common 
internal standard and were not background-subtracted.
A closed formula from Hsieh et al,40 relating sample size 
to observable effect size, was used to calculate sample size 
Figure 3 Study flow chart. Figure outlines the patient journey from admission through to discharge and follow-up. Participants 
with self-reported acute breathlessness presenting to University Hospitals of Leicester are recruited within 24 hours following 
a senior decision maker review. Breath sampling is carried out on the first visit, at recruitment, and the second visit, up to 
6 months after discharge. Patients are admitted through the standard operational emergency medical streaming and care 
pathways at the University Hospitals of Leicester National Health Service Trust. Early outcomes (hospital readmission) are 
measured at 30 days and 60 days and late outcomes (mortality) including respiratory and all-cause mortality are measured 
at 2 years. Assessments carried out at each time point are summarised in table 1. APCI-MS, atmospheric pressure chemical 
ionisation-mass spectrometry; GC-IMS, gas chromatography ion mobility spectrometry; GC-MS, gas chromatography mass 
spectroscopy; GC×GC-MS, two-dimensional gas chromatography-mass spectrometry.
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from logistic regression models of the ten aldehydes with 
acute breathlessness as the outcome measure. The sample 
size estimates are also relevant to acute class comparisons 
versus the sum of other acute classes.
Based on the sample size estimates, we would have 
an 80% power, with a type 1 error rate of 5%, to detect 
an OR of association of 1.2 between two disease classes 
with 55 patients per class. Given the fact that study 
seeks to discover and replicate breath VOC among five 
adult disease classes (community-acquired pneumonia, 
heart failure, COPD, asthma and healthy aged-matched 
subjects), we would require 110 adult patients per class—
550 patients across the programme to achieve these aims.
The closed formulae by Hajian-Tilaki et al41 were 
also used to understand the discriminatory power that 
the samples sizes above would provide with respect 
to biomarker sensitivity and specificity; the following 
assumptions were made:
 ► That a sensitivity of 80% with a precision of 5% would 
provide a useful biomarker capable of ‘ruling out’ an 
acute class. The same target was applied to specificity.
 ► We assume a prevalence of acute breathlessness of 
80% as the recruitment campaign uses acute breath-
lessness as the initial stratification tool for recruit-
ment and 1:5 patients recruited will be non-breathless 
healthy controls.
 ► We aim to balance group sizes across classes equally.
For a type 1 error rate of 0.05 and a 95% CI:
Nsensitivity=307.
Nspecificity=1230.
For a type 1 error rate of 0.05 and a 90% CI:
Nsensitivity=218.
Nspecificity=871.
For a type 1 error rate of 0.05 and an 85% CI:
Nsensitivity=166.
Nspecificity=664.
For a type 1 error rate of 0.05 and an 80% CI:
Nsensitivity=131.
Nspecificity=524.
Therefore, we are powered to identify sensitive 
biomarkers (≥80%) of acute breathlessness with a 
maximum marginal error in the estimate for sensitivity 
not exceeding 5% with 95% confidence. Similarly, we 
are powered to identify specific biomarkers (≥80%) of 
acute breathlessness with a maximum marginal error in 
the estimate for specificity not exceeding 5% with 80% 
confidence.
For the primary analysis, the outcome will be treated 
as a nominal variable with levels: (1) acute heart failure, 
(2) community-acquired pneumonia; (3) adult exacer-
bations of asthma and COPD; and (4) acute exacerba-
tions in school-age children treated in hospital for severe 
asthma attacks.
The relationship between the primary outcome and the 
exhaled breath VOC biomarkers will be modelled using 
multinomial logistic regression. In addition to metabo-
lomics markers, the following independent variables will 
be included in the model: clinical uncertainty score on a 
100 mm VAS scale, age and a validated comorbidity score 
(the Charlson comorbidity score).42 43
Receiver operator analyses will be used to generate 
reciver operating characteristic curves for individual 
and multiple panels VOC predictors in the primary 
analysis.
To understand the dynamic profile of breath 
biomarkers during (1) the acute state and (2) in the 
chronic state up to 6-month postexacerbation, a repeated 
measures model with a random intercept and random 
effect for time will be fitted; the random effects will be 
fitted for each patient. For the repeated measures mixed 
model, an unstructured covariance will be assumed. To 
evaluate the relationship between breath biomarkers 
and hospital readmission at 30 and 60 days, Cox propor-
tional hazards and frailty models will be used.44 Analysis 
of multivariate survival data, competing risk models and 
joint models will be fitted.45 Relationship between death 
and breath biomarkers will be evaluated using a logistic 
regression model. Changes in outcome measures will 
be measured appropriately for each variable (eg, paired 
t-test, Mann-Whitney and repeated measures anal-
ysis). Tables of descriptive statistics will be compiled for 
all key variables.
All analysis will be performed using R V.3.5.0 (https://
www. r- project. org/).
discovery and replication studies
Specific indicator conditions have been selected for 
targeted recruitment according to their high prevalence 
and unmet need, their high morbidity and mortality and 
the need to develop better diagnostic and prognostic 
algorithms in acute care pathways.
The indicator diagnoses of interest are: (1) exacer-
bations of adult asthma and COPD, (2) community-ac-
quired pneumonia, (3) acute heart failure; and (4) 
exacerbation in school age children treated in hospital 
for severe asthma attacks.
Patient-level clinicopathological and outcome data 
(spanning the entire acute pathway) will be collected in 
parallel to breath sampling. In addition, breath samples 
will be acquired in the stable state post exacerbation 
(figure 3).
Age-matched healthy volunteers will be recruited where 
possible at separate visits. For the purposes of this study, 
healthy volunteers will be defined as participants who 
have no prior history of asthma, COPD, heart failure 
and have not been admitted to hospital with community 
acquired pneumonia within 6 weeks of the baseline study 
visit. For acute admission, the study team will approach 
the spouse, parent or sibling of the index case and seek 
informed consent for study assessments. All healthy 
subjects will undergo two assessments separated by a 
duration of 8–16 weeks to match the acute and recovery 
time points elapsed in their index case/partner/spouse/
sibling/child. Additional healthy volunteers will be iden-
tified from local recruitment databases and via advertising
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Discovery phase (project months 1–24)
The aim of the discovery phase is to discover putative 
discriminatory breath VOC, using both offline and online 
technologies.
Preplanned recruitment of acutely breathless patients 
will be enriched into the following disease strata following 
senior clinical decision maker assessment and within 
24 hours of acute admission.
Acute adult heart failure (n=55), adult community-ac-
quired pneumonia (n=55), adult exacerbations of asthma 
(n=55) and COPD (n=55) in addition to acute severe 
asthma attacks in school-age children (n=50).
Additional age-matched healthy volunteers (n=55 
adults and 50 children) will be identified as a non-disease 
reference group (table 1).
Replication phase (years 3–4)
The aim of the replication phase is to replicate putative 
discriminatory breath VOC/VOC signatures identified in 
the discovery phase.
Similar to the discovery phase, recruitment of acutely 
breathless patients will be enriched into the following 
disease strata following senior clinical decision maker 
assessment and within 24 hours of acute admission.
Acute adult heart failure (n=55), adult community 
acquired pneumonia (n=55), adult exacerbations of 
asthma (n=55) and COPD (n=55) in addition to acute 
severe asthma attacks in school age children (n=25) 
(table 1).
Additional age-matched healthy volunteers (n=55 
adults and 25 children) will be identified as a non-disease 
reference group.
schedule of assessments
A schedule of acute assessments is outlined below and 
aligns to the movement of acute patients through the 
clinical care pathway and the overall aim of developing 
a complete phenotypic picture of acutely breathless 
patients.
Defining acute breathlessness
At presentation (within 24 hours of admission) to one of 
three acute admissions units, potentially eligible patients 
will be identified following confirmation of acute breath-
lessness, identified as: (1) patient-defined acute breath-
lessness and/or (2) 1 unit increase above patient reported 
baseline in the extended MRC (eMRC) dyspnoea 
score46 47 and at least one of the indicator diagnoses iden-
tified as the primary clinical diagnosis by a senior clinical 
decision maker. eMRC will be completed by all patients 
and healthy volunteers at each research visit.
Informed consent
Patients meeting the prespecified definition of acute 
breathlessness will be approached for informed consent 
to the breath VOC biomarker study. Only patients that 
are eligible to give full written informed consent will be 
recruited.
Collection of blood-based pathology markers
Collection of the blood biomarkers CRP, BNP, tropo-
nin-I and blood eosinophil count will be performed both 
acutely and following recovery, when not taken as part of 
clinical care pathway. These are currently used in profiling 
acutely breathless patients in clinical practice (table 2).
Breath VOC sampling
Offline breath sampling using GC-MS and comprehensive 
GC×GC-MS coupled with a standardised and CE-marked 
breath sampler ReCIVA48 will be performed. Gas chro-
matography is considered a gold standard technique in 
detecting VOCs and as such its sampling will be priori-
tised. Additionally, the following online technologies, 
proton transfer reaction mass spectroscopy (PTR-MS), 
gas chromatography ion mobility spectrometry (GC-IMS) 
and atmospheric pressure chemical ionisation-mass spec-
trometry (APCI-MS) will be evaluated according to the 
sampling strategy outlined in figure 3 and table 3.
Collection of additional samples for future biomarker campaigns
Collection of additional biomarkers for future biomarker 
discovery campaigns including: (1) a urine sample, (2) 
blood samples, up to 85 mL for DNA, RNA, plasma and 
serum and peripheral blood cell flow cytometry in selected 
subjects and (3) spontaneous or induced sputum samples 
(plugs and supernatants) will be carried out (table 3).
All samples will be collected at time points 1 and 2 
(figure 3). The additional samples will be used for future 
omics analyses, these may include detailed analysis of the 
metagenome in sputum and proteomics applied to urine 
and serum samples.
Physiological characterisation
Physiological measures of lung function will be 
performed in acutely ill participants and at recovery 
including: (1) handheld forced oscillation technique: 
an easily accessible measure of lung function. Patients 
favour this to spirometry as it is effort independent, 
unlike spirometry, and requires less than a minute of 
Table 1 Table summarising recruitment targets for both 
adult and paediatric groups. Total combined sample size of 
the discovery and replication  phases = 700  participants.
Disease category Discovery Replication
Acute adult asthma 55 55
Acute chronic obstructive 
pulmonary disease 
55 55
Acute heart failure 55 55
Community-acquired pneumonia 55 55
Adult healthy volunteers 55 55
Acute paediatrics asthma 50 25
Paediatrics healthy volunteers 50 25
Total sample 375 325
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quiet tidal breathing to obtain triplicate high-quality 
measurements,49 This will be completed using Tremoflo, 
Thorasys Thoracic Medical Systems Inc. (2) Fractional 
exhaled nitric oxide: a measure of airway inflammation 
in patients with asthma.50 51 This instrument used for this 
will be NIOX VERO, registered trademark of Circassia 
AB (PP-VERO-UK-0022-V.1.0). (3) Echocardiography: 
two-dimensional transthoracic echocardiography will be 
performed in heart failure and COPD patients using an 
iE 33 system with S5-1 transducer (frequency transmitted 
1.7 MHz, received 3.4 MHz; Philips Medical Systems, Best, 
The Netherlands). Standard techniques as per American 
Society of Echocardiography guidelines (ASE)52 will be 
used to acquire two-dimensional, colour and Doppler 
images in conventional parasternal long-axis, short-axis 
and apical 4-chamber, 2-chamber and 3-chamber views. 
Left ventricular ejection fraction will be calculated using 
the biplane method of discs formula (Simpson’s rule) to 
derive left ventricular volume indices.
All participants are encouraged to report any testing-re-
lated discomfort or concerns to the research team to 
terminate the sampling process.
Recovery follow-up
 ► Patient recovery will be defined as:
i. Patient-reported recovery from the acute exacer-
bation spell and back to their baseline-extended 
MRC score or clinician-defined recovery from the 
acute exacerbation spell.
ii. At least 6 weeks postexacerbation event (up to 6 
months).
Patients who readmit to hospital between visits 1 and 
2 can have additional visit 1 assessments. Visit 2 will be 
taken as recovery following the subsequent admission. If 
a patient is admitted to hospital after visit 2, then they will 
be eligible to be recruited as a new study participant.
The schedule of assessments at the recovery visit is 
outlined in table 3.
Clinical adjudication
In an effort to reduce data variability and minimise bias, 
an independent panel consisting of two senior acute clini-
cians (SS and NG) will review all pertinent clinical and 
diagnostic source documentation while blinded to admis-
sion blood biomarkers and clinical diagnosis.
All acutely breathless adult patients’ notes will be 
sequentially divided for adjudication. The panel will inde-
pendently determine the primary diagnosis of highest 
probability from a list of the four potential acute indi-
cator diagnoses and mark their level of clinical certainty 
on a 100 mm VAS. The panel members will be able to 
review imaging, ECGs and other relevant information but 
not admission blood-based pathology tests.
In a subset of patients, adjudication will be validated 
by separate panel member to ensure between observer 
agreement using Bland-Altman analysis and inter-rater 
agreement of the primary diagnosis using Kohen’s kappa 
via repeated evaluation of a subset of cases (see statistical 
methods outlined).
Clinical informatics
Clinical data collection will be undertaken using a 
securely hosted bespoke database system (ADD) devel-
oped within the National Institute for Health Research 
(NIHR) Leicester Biomedical Research Centre – Respi-
ratory (BRC). The system links acute admission episodes 
to hospital pathology records; historical respiratory phys-
iology tests; and demographic information. The system 
provides functionality to validate data entry, manually 
verify records and highlight incomplete records. A 
custom VOC ‘module’ has been be created to support 
data collection within the study visits (1 and 2) and stan-
dardise diagnoses and medications through the use of 
clinical ontologies as well as linking hospital records/tests 
to patient visits.
Non-ADD-based clinical data (eg, hospital admissions, 
readmissions and mortality) will be extracted from 
the hospital data warehouse using identifiable patient 
Table 2 Type of analyser and methodology used for blood biomarker calculation
Test Analyser/method
Lower limit of 
detection Upper limit of detection
C reactive protein Siemens Advia Chemistry XPT, Polyethylene 
Glycol enhanced immunoturbidimetric 
assay.
Siemens Advia 1800, Polyethylene Glycol 
enhanced immunoturbidimetric assay.
5 mg/L Diluted to result
B-type natriuretic peptide Siemens Advia Centaur XPT, two-site 
sandwich immunoassay using direct 
chemiluminescent technology.
2.0 pg/mL 1445 pg/mL
Troponin-I Abbott Architect i2000SR, three-site 
sandwich immunoassay using direct 
chemiluminescent technology (CMIA).
5.0 ng/L 50 000 ng/L
The table outlines analyser make, methodology, upper and lower limits of detection as per the University Hospitals of Leicester National 
Health Service Foundation trust laboratory guidelines.
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identifiers and subsequently pseudonymised prior to 
integration.
An informatics pipeline will be created to facilitate the 
transfer of chemometric data from remote computers to 
the data repository. This will include tools to: (1) enforce 
the correct labelling of data sets (eg, study number, 
visit and type/source of sample) prior to automated vali-
dated transfer to the repository; (2) record information 
about the sample process; and (3) search and extract data 
sets from the repository for subsequent analysis. Prior to 
analysis, clinical and chemometric data will be integrated 
using the study number and any potentially identifiable 
information will be removed.
brEAth profIlIng
The technologies used in the VOC study during discovery 
and replication phases are:
Offline technologies:
 ► ReCIVA+GC-MS.
 ► ReCIVA+GC ×x GC-MS.
Online technologies:
 ► GC-IMS.
 ► PTR-MS.
 ► APCI-MS.
Offline technologies will underpin the discovery anal-
yses owing to their ability to identify chemical identity 
and their recognition as the analytical gold standard in 
exhaled breath VOC analysis.53
In contrast, online technologies will be used for VOC 
biomarker replication and at the recovery visits owing 
to their portability and potential for future point of care 
testing (figure 4). A brief description of the core VOC 
platforms is provided below.
A CE-marked breath sampling device (ReCIVA) devel-
oped by Owlstone Medical will be used to sample breath 
onto two adsorbent Tenax tubes. Participants will be 
asked to breathe through the ReCIVA face mask for a 
maximum of 900 seconds, aiming for collection of ≥80% 
of the target sample volume of 1 L, after which the Tenax 
tubes will be transferred to the laboratory for analysis. 
This effectively allows decoupling of the breath sampling 
from the breath sensor and analysis platforms in selected 
patients that are not able to mobilise to a real-time breath 
sampling device. The Owlstone ReCIVA sampler will be 
used in breath collection for offline technologies namely 
GC-MS and GC×GC-MS. The ReCIVA sampler is capable 
of entraining oxygen and is therefore suitable for patients 
with mild respiratory failure requiring low flow rates of 
oxygen to maintain target oxygen saturations.48
gas chromatography and mass spectroscopy
GC-MS is a commonly applied methodology used to accu-
rately measure trace gases in complex mixtures such as 
exhaled air.53 Preconcentrating breath volatiles by various 
means and subsequent analysis constitute a reliable and 
sensitive method for VOC analysis.54 Despite its high 
sensitivity, it is, however, a time-consuming technique 
Figure 4 Multi-instrument use in breath sampling. Operational space of the analytical technologies used in EMBER for the 
analysis of volatile organic compounds in exhaled breath, including proton transfer reaction mass spectrometry (PTR-MS), 
atmospheric pressure chemical ionisation-mass spectrometry (CMS), gas chromatography ion mobility spectrometry (GC-IMS), 
gas chromatography mass spectrometry (GC-MS) and two-dimensional gas chromatography-mass spectrometry (GC×GC-
MS). Comparing the typical molar mass range detectable; selectivity in detection owing to the type of ionisation involved and 
the proton affinity of analytes; and the inclusion of a chromatographic separation affecting total time of analysis. The online 
technologies involving chemical ionisation (PTR-MS, CMS and GC-IMS) can be used in-clinic owing to short analysis times but 
only detect lower molar mass molecules with a proton affinity higher than 697 KJ/mol. Offline chromatographic techniques (GC-
MS and GC×GC-MS) detect a wider range of compounds independent of proton affinity; however, the techniques have longer 
analysis times and involve sample transportation and storage. EMBER, East Midlands Breathomics Pathology Node.
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and carries a risk of contamination at the preconcentra-
tion step. It is also not suitable for online and multiple 
measurements limiting its use as a point-of-care testing 
technology for VOC.55
The instrument used will be an Agilent 7890A gas chro-
matogram with a 5977a quadrupole mass spectrometer 
(Agilent Technologies Ltd, Stockport, UK), interfaced 
with a Markes Unity 2 thermal desorptionunit (Markes 
International Ltd, Llantrisant, UK).
Comprehensive two-dimensional gas chromatography-mass 
spectrometry (gC×gC-Ms)
GC×GC-MS is an advanced analytical technique for the 
analysis of complex organic matrices; its main advantage is 
the unparalleled separation power it affords over conven-
tional one-dimensional chromatographic techniques.56 
Previous research, although sparse, has demonstrated 
the potential of GC×GC-MS for breath analysis with the 
number of VOC detected exceeding those detected by 
conventional GC-MS.57 58 GC×GC-MS of breath metabo-
lites has been used for the identification of biomarkers 
related to glucose metabolism,59 60 tuberculosis61 and radi-
ation response.62 This has generated interest within the 
breath research community; however, such studies were 
conducted on a small scale (<50 patients) and involved 
the use of expensive detectors and modulators. Method 
development and analysis of the data-rich GC×GC chro-
matograms, however, can be time-consuming and require 
specialist knowledge.
The instrument used will be an Agilent 7890A gas chro-
matogram, fitted with a G3486A CFT flow modulator and 
a three-way splitter plate coupled to a flame ionisation 
detector and a HES 5977B quadrupole mass spectrometer 
(Agilent Technologies Ltd, Stockport, UK), interfaced 
with a Markes TD-100xr thermal desorption autosampler 
(Markes International Ltd, Llantrisant, UK).
Proton Transfer Reaction Time-of-Flight Mass Spec-
tromery  (PTR-ToF-MS) is a real-time technique, capable 
of simultaneously measuring the evolution of multiple 
gas metabolites from a single breath. It has been used 
for the identification of potential useful VOC biomarkers 
for diagnosis of a variety of diseases including various 
cancers,63–65 liver disease66 67 and respiratory disease.68 
It has several advantages in clinical settings, such as the 
speed of sampling, the instant result achieved and the lack 
of need for sample storage or shipping. However, owing 
to the lack of preconcentration or chromatographic sepa-
ration, sensitivity and definitive compound identification 
can be somewhat limited when compared with GC-MS.
Two breath sampling devices will be used. The first 
device is a Loccioni SOFIA GSI-S; the subject is required 
to exhale a single breath, five times (three if providing 
five samples proves too difficult) into a sterile mouth-
piece connected to an electrostatic bacterial/viral filter 
while wearing a nose clip (all CE marked). Flow from the 
mouthpiece passes into a gas sampling interface capno-
graph (Loccioni GSI-S – CE marked), and real-time user 
feedback of flow is provided on screen, allowing the 
regulation of the breath sampling rate. The gas sampling 
interface acts to simultaneously trigger the acquisition of 
the Proton Transfer Reaction Time-of-Flight Mass Spec-
tromery (PTR-ToF-MS) data and the exhaled breath 
travels through the capnograph down a heated sample 
line into the ion source of the PTR-ToF-MS.
The second breath sampling device is a ReCIVA breath 
sampler (Owlstone) with one of the adsorbent Tenax 
tubes replaced with an outlet tube adapted for online 
sampling. The exhaled breath is transferred to the 
PTR-ToF-MS via a heated transfer line connected to the 
outlet tube, continuously drawn at a constant flow rate by 
the PTR-ToF-MS. The online adaptation of the consum-
able adsorbent tube does not affect the CE mark of the 
ReCIVA sampling device.
Once the breath sample reaches the PTR-ToF-MS, via 
either breath sampler, the breath mixes with proton-
ated water (H3O
+) inducing proton transfer to the target 
VOCs present, resulting in their ionisation. Sample ions 
are then guided into the time of flight mass spectrometer, 
and mass spectra, showing the abundance and mass of 
the VOCs present, collected throughout the exhalation. 
Following sampling, mouthpieces, filters and nose clips 
are disposed of, and all patient-contacted surfaces were 
wiped down with antiseptic cleaning wipes in preparation 
for the next patient.
The instrument used will be a Kore Series II high 
performance proton transfer reaction time of flight-mass 
spectrometer (Kore Technology Ltd, Cambridge, UK).
gas chromatography - Ion Mobility spectrometry (gC-IMs) 
(b&s Analytiks)
GC-IMS allows the detection of VOCs down to ultratrace 
level (µg/L – to pg/L – range). For years, IMS has been 
used to discover potential discriminatory breath VOC in 
lung cancer,69 70 chronic obstructive pulmonary disease 
(COPD)71 72 and asthma.72 Sampling takes place using 
a Spiroscout spirometer. The patients exhale through 
a disposable mouth piece connected to a Teflon tube. 
A piezoelectric pressure sensor is used to monitor the 
breathing profile; this opens the sampling valve at the 
appropriate point in the breath profile to collect end-tidal 
breath in a sample loop of 10 mL volume. After filling 
this loop, the collected sample air is then transferred to a 
multicapillary column for a chromatographic separation, 
which is achieved in 12 min. The separated molecules are 
then transferred into the IMS, ionised and then separated 
according to their mobility in a weak electric field.
The technology’s multiple advantages of ultrasensi-
tivity, portability, online sampling and short analysis time 
(typical analysis time of 10 min) with real-time detection 
brings a promise to provide immediate and potentially reli-
able results for point of care breath diagnostics. Another 
concept with IMS devices is that once the required breath 
signatures have been discovered using GC-MS, IMS offers 
the potential to be ‘tuned’ for selective detection of VOC.
The instrument used will be a BioScout a multicapillary 
column GC-IMS with a 63Ni ion source, interfaced with 
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a SpiroScout breath sampler (BS Analytik, Dortmund, 
Germany).
ApCI-Ms semiportable compact version (Advion)
APCI-MS is one of less sensitive but more affordable 
versions of mass spectrometers released to the commer-
cial market in recent years. The device uses APCI to 
produce ions. Although the most common use of APCI-MS 
systems is the detection in liquid chromatography appli-
cations, the technique has proven to be a valuable tool 
for direct measurement of VOC in air,73 74 food75 76 and 
breath.77 78 Recently, the technique has shown potential 
for online, real-time profiling of pseudometabolites in 
exhaled breath79 with sensitivity comparable with other 
techniques. By combining miniaturised mass spectrom-
etry technology with APCI techniques, adequate quality 
of on-site, real-time measurements with minimal or no 
sample preparation requirement can be provided. This 
is a desirable outcome as it overcomes main limitation of 
using standard breath analysis method in clinical setting, 
which is a need for breath sample collection followed by 
desorption and time-consuming laboratory analysis.
Preconcentrating breath gas by various means and 
subsequent analysis by means of GC-MS constitute a reli-
able and sensitive set of methods for VOCs analysis.
There remains an overall lack of standardisation and 
rigour across these technologies that hindered previous 
advancements in breath discovery; something we intend 
to minimise.
The instrument used will be an Advion Compact Mass 
Spectrometer Express, with atmospheric pressure chem-
ical ionisation, interfaced with a heated breath sampling 
line (Advion, New York, USA).
ChEMoMEtrIC proCEssIng And dAtA AnAlysIs
GC-MS breath data will be aligned, deconvoluted and 
the features for each participant will be extracted. The 
extracted features will be grouped and classified by 
retention index and mass spectrum. The registered and 
aligned data will be linked to participant metadata to 
generate a breath matrix. Data handling and analysis will 
be performed by a senior statistician.
The breath matrix is a × matrix where n is the number of 
subjects and p is the number of VOC. The breath matrix is 
high dimensional with ≫ and many potentially correlated 
VOC. In view of this, we will employ sparse partial least 
squares discriminant analysis80 to investigate which of the 
VOC can identify breathlessness. We will also investigate 
which of the VOC can discriminate between the different 
disease states including acute exacerbations of asthma 
and COPD and pneumonia. In addition to the supervised 
methods, unsupervised methods will be explored, specifi-
cally sparse principle component analysis.81
Extracted VOC will also be investigated. Relationships 
between VOC and patient-reported acute breathlessness 
will be analysed using logistic regression model. VOC 
associated with patient reported acute breathlessness 
will be incorporated into multinomial logistic regression 
models in conjunction with CRP, BNP, blood eosinophils 
and troponin-I, pathology biomarkers currently in use 
for diagnosing undifferentiated breathlessness. In addi-
tion to the conventional binary and multinomial logistic 
regression models.82
EthICs And dIssEMInAtIon
Publications will be prepared according to the 
MRC-EMBER consortium agreement and the University 
of Leicester publications policy. All intended publica-
tions will be submitted to the EMBER executive board 
for review and comments within 60 days of journal 
submission. Authorship will be according to contribu-
tion and internationally recognised guidance on journal 
authorship.
patient and public involvement
A series of consultations have taken place with our patient 
involvement team within the NIHR Biomedical Research 
Centre (Respiratory Theme) and across the wider BRC 
patient and public involvement group. Representations 
from the paediatrics team were also present. This group 
was sent copies of the participant documentation for 
review and discussion. Various revisions have been made 
following on from these discussions.
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